- Conditions
- Sickle Cell Disease
- Interventions
- FDNIRS-DCS, MRI
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 640
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Myelogenous Leukemia, Lymphoblastic Leukemia
- Interventions
- Tacrolimus, Sirolimus, G-CSF, Antithymocyte globulin, Thymoglobulin, Fludarabine, Melphalan
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Blood Loss After Primary Total Joint Arthroplasty, Need for Blood Transfusion After Total Joint Arthroplasty
- Interventions
- Oral Tranexamic Acid, Intravenous Tranexamic Acid
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alzheimer&Amp;#39;s Disease
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe Aplastic Anemia, Refractory, Non-severe Aplastic Anemia
- Interventions
- Dibotatug (DR-01)
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 10
- States / cities
- Duarte, California • Palo Alto, California • Miami, Florida + 7 more
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
- Interventions
- Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care
- Drug · Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 35
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more
- Conditions
- Twin Twin Transfusion Syndrome
- Interventions
- Doppler ultrasound of fetal renal artery
- Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Female only
- Enrollment
- 24 participants
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Transfusion Transmitted Babesiosis
- Interventions
- B.microti diagnostic blood tests
- Biological
- Lead sponsor
- Imugen
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 90,116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Norwood, Massachusetts
- Conditions
- Leukemia, Myeloma, Myelodysplastic Syndromes, Hematologic Malignancy, Hematologic Diseases, Lymphoma
- Interventions
- HEME-Hospice Program
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Jason Robert Gotlib
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islet transplant, Antithymocyte globulin, Basiliximab, Lisofylline, Sirolimus, Tacrolimus
- Procedure · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Miami, Florida • Chicago, Illinois
- Conditions
- Coagulopathy
- Interventions
- ROTEM, Cryoprecipitate, RiaSTAP
- Device · Other · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteoarthritis, Intraoperative Bleeding
- Interventions
- Evicel Fibrin Spray
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Oak Park, Illinois
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Highland, California • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Fetofetal Transfusion
- Interventions
- Not listed
- Lead sponsor
- Catherine Cibulskis, MD
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neonatal Thrombocytopenia
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Days to 6 Months
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Patients Who Are in Shock and Intubated in the Trauma Bay (TB)
- Interventions
- Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound), Usual care
- Device · Other
- Lead sponsor
- Riverside University Health System Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Moreno Valley, California
- Conditions
- Peripartum Anemia
- Interventions
- Intraoperative cellular salvage
- Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
- Device · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiovascular Diseases
- Interventions
- Quantra QPlus System
- Diagnostic Test
- Lead sponsor
- HemoSonics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Prescott, Arizona
- Conditions
- Squamous Cell Carcinoma, Non-Small-Cell Lung
- Interventions
- Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 91
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
- Conditions
- Anemia
- Interventions
- INTERCEPT, Control
- Device
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- 11 Years and older
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more
- Conditions
- Blood Loss, Hip Arthritis, Knee Arthritis
- Interventions
- Amicar, TXA
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
- Interventions
- Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York